INKT MiNK Therapeutics
Price Chart
Executive Summary
MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for severe acute lung injury/ARDS. This is a clinical milestone with no revenue or earnings data, and preliminary efficacy readout is not expected until 2H 2026, making the near-term stock impact limited.
Actionable Insight
Traders should view this as an expected clinical execution update with no material stock-moving data. The next meaningful catalyst is the preliminary data readout in 2H 2026. Until then, there is no new fundamental information to alter the risk/reward profile.
Key Facts
- First patient dosed in randomized Phase 2 trial (C-1300-02) for agenT-797 in severe acute lung injury/ARDS patients
- Trial compares agenT-797 + standard of care vs placebo + standard of care; primary endpoints include survival, ventilator-free days, and ICU recovery
- Dosing occurred at First Lviv Territorial Medical Union in Ukraine, with U.S. site expansion underway
- Preliminary data expected in second half of 2026 — no near-term catalyst
- agenT-797 is an off-the-shelf allogeneic iNKT cell therapy, delivered without patient-specific manufacturing or HLA matching
- No financial figures, guidance, or material agreements disclosed in the press release
Financial Impact
No revenue, earnings, or financial guidance disclosed — pre-revenue clinical-stage company with $51M market cap
Risk Factors
- Phase 2 trial may fail to meet endpoints, potentially wiping out clinical value of agenT-797 in this indication
- Enrollment in Ukraine faces geopolitical and operational risks
- Pre-revenue company with limited cash runway — future financing risk exists
- Historical model performance on INKT shows negative average T+20 alpha (-9.76% vs SPY), suggesting the stock has underperformed following prior reports
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302945 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
Press Release
| $12.20 $12.76 | ▲ +4.59% | ▲ +4.64% | $11.34 (−7.05%) |
|
May 20, 2026
20d ago
|
Press Release
| $10.72 $10.18 | ▼ −5.04% | ▼ −6.27% | $11.34 (+5.78%) |
|
May 15, 2026
25d ago
|
8-K
| $10.72 $10.87 | ▲ +1.40% | ▲ +0.44% | $11.34 (+5.78%) |
|
May 15, 2026
25d ago
|
Press Release
| $10.72 $10.87 | ▲ +1.40% | ▲ +0.44% | $11.34 (+5.78%) |
|
May 14, 2026
26d ago
|
Press Release
| $10.51 $10.94 | ▲ +4.09% | ▲ +4.81% | $11.34 (+7.90%) |
|
May 12, 2026
28d ago
|
Press Release
| $11.41 $10.04 | ▼ −12.01% | ▼ −12.08% | $11.34 (−0.61%) |
|
May 8, 2026
4w ago
|
Press Release
| $10.95 $10.04 | ▼ −8.31% | ▼ −8.23% | $11.34 (+3.56%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $14.21 $10.95 | ▼ −22.94% | ▼ −23.50% | $11.34 (−20.20%) |
|
Apr 1, 2026
9w ago
|
Press Release
| $10.57 $11.47 | ▲ +8.51% | ▲ +4.75% | $11.34 (+7.28%) |
|
Mar 31, 2026
10w ago
|
8-K
| $10.53 $11.15 | ▲ +5.89% | ▲ +1.94% | $11.34 (+7.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access